Clinical trials: Invasive Breast Cancer Early Stages
Breast Cancer, Breast Cancer Invasive
Specimen PET-CT Imaging for Intraoperative Margin Assessment in Breast Cancer
Breast-conserving surgery (BCS) has become the standard-of-care for surgical management of the majority of women with early-stage breast cancer.
- Conditions
- Breast Cancer, Breast Cancer Invasive, Breast Cancer in Situ
- Trial name
- BrIMA (NCT04999917)
- Testing
- high-resolution PET-CT specimen imaging.
- Where
- Belgium
- Volunteers
- 206 people
- Sponsor
- XEOS Medical
Breast Cancer
Prospective Validation of Ataraxis AI Test for Predicting Treatment Response in Neoadjuvant Breast Cancer
This study evaluates the real-world clinical workflow integration of a previously developed artificial intelligence (AI) prognostic test in breast cancer patients receiving neoadjuvant chemotherapy, and validates its accuracy in…
- Trial name
- ATARAXIS NEOP (NCT07327970)
- Testing
- multi-modal foundation AI test
- Where
- South Korea
- Volunteers
- 150 people
- Sponsor
- Young-Joon Kang
Cancer
Early Intervention vs. Standard Palliative Care in Improving End-of-Life Care in Advanced Cancer Patients
RATIONALE: Palliative care may help patients with advanced cancer live more comfortably. PURPOSE: This randomized clinical trial is studying an early intervention palliative care program to see how well it works compared to a…
- Trial name
- NCT00253383
- Testing
- counseling intervention, educational intervention, psychosocial assessment and care
- Where
- 2 sites in United States
- Volunteers
- 329 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Breast Cancer
IORT Following Breast Conserving Surgery for Early Stage Breast Cancer Registry
This is a prospective, registry trial which will enroll women aged 65 and above with early stage, low risk breast cancer who will be treated with partial mastectomy and intraoperative radiation therapy (IORT).
- Trial name
- NCT03536897
- Testing
- IORT
- Where
- United States
- Volunteers
- 168 people
- Sponsor
- Mount Carmel Health System
Breast Cancer
Radiation Therapy in Treating Women Who Have Undergone Surgery for Early-Stage Invasive Breast Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. Radiation to the tumor site and surrounding area may kill more tumor cells.
- Trial name
- NCT00005957
- Testing
- Standard Breast Irradiation, Breast Radiation plus Regional Radiation
- Where
- 26 sites in Canada
- Volunteers
- 1,832 people
- Sponsor
- NCIC Clinical Trials Group
Breast Cancer
Radiation Therapy Using Gold Markers in Treating Women With Early-Stage Breast Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Placing gold markers in the area where the tumor was removed may help doctors better direct radiation therapy and help reduce the risk of cancer…
- Trial name
- NCT00749437
- Testing
- 3-dimensional conformal accelerated partial breast irradiation
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- University of Medicine and Dentistry of New Jersey
Breast Cancer, Breast Cancer Female
Preoperative Stereotactic Ablative Body Radiotherapy (SABR) for Early-Stage Breast Cancer
This study involves a course of radiation to the tumor that is delivered BEFORE surgery. The type of radiation is called stereotactic ablative body radiation therapy (SABR).
- Conditions
- Breast Cancer, Breast Cancer Female, Breast Adenocarcinoma
- Trial name
- NCT03137693
- Testing
- Standard of Care Schedule Variation: SABR, Breast-conserving Surgery
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Breast Cancer Invasive, Early-stage Breast Cancer
BRE-04: Window of Opportunity Trial of Preoperative Low Dose Azacitidine in High-Risk Early Stage Breast Cancer
To determine the effect of low dose azacitidine therapy on tumor infiltrating lymphocytes (TILs) in primary tumors from patients with high-risk early stage breast cancer, paired t-tests will be first used to compare TIL count in…
- Conditions
- Breast Cancer Invasive, Early-stage Breast Cancer, High Risk Breast Carcinoma
- Trial name
- BRE-04 (NCT04891068)
- Testing
- Azacitidine
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Illinois at Chicago
HER2-normal
Dose Dense Doxorubucin and Cyclophosphamide Followed by Eribulin Mesylate for the Adjuvant Treatment of Early Stage Breast Cancer
The purpose of this study is to assess the feasibility of dose-dense doxorubicin and cyclophosphamide followed by eribulin mesylate for adjuvant treatment of early stage breast cancer.
- Trial name
- NCT01328249
- Testing
- eribulin mesylate
- Where
- 2 sites in United States
- Volunteers
- 81 people
- Sponsor
- Eisai Inc.
Early-stage Breast Cancer, Hormone Receptor Positive Breast Carcinoma
Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer
This phase II trial investigates how well trastuzumab deruxtecan works alone or in combination with anastrozole in treating patients with HER2 low, hormone receptor positive breast cancer.
- Conditions
- Early-stage Breast Cancer, Hormone Receptor Positive Breast Carcinoma, Invasive Breast Cancer, Stage II Breast Cancer
- Trial name
- NCT04553770
- Testing
- Anastrozole, Therapeutic Conventional Surgery, Trastuzumab Deruxtecan
- Where
- 9 sites in United States
- Volunteers
- 88 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Breast Cancer
Radiation Therapy in Women With Low Risk Early-Stage Breast Cancer Who Have Undergone Breast Conservation Surgery
RATIONALE: Radiation therapy uses high-energy x-rays to kill tumor cells. Giving radiation therapy after surgery may kill any tumor cells that remain after surgery.
- Trial name
- IMPORT (NCT00814567)
- Testing
- radiation therapy
- Where
- United Kingdom
- Volunteers
- 2,018 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Breast Cancer Invasive, Hormone-receptor-positive Breast Cancer
Neoadjuvant Pyrotinib in HR-positive and HER2-low High-risk Early Breast Cancer
This is a multi-center, open-lable, prospective, randomized phase III clinical trial to further validate the efficacy and safety of neoadjuvant pyrotinib combined with chemotherapy in HR-positive/HER2-low (IHC 2+/FISH-negative)…
- Conditions
- Breast Cancer Invasive, Hormone-receptor-positive Breast Cancer, HER2 Low Breast Carcinoma, Early-stage Breast Cancer
- Trial name
- NCT06144944
- Testing
- Pyrotinib, epirubicin or doxorubicin, cyclophosphamide, paclitaxel, Epirubicin or doxorubicin, cyclophosphamide, paclitaxel
- Where
- China
- Volunteers
- 160 people
- Sponsor
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Tubular Breast Cancer Stage II, Tubular Breast Cancer Stage III
A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)
Two regimen are currently considered to have highest efficacy for patients with high-risk early stage breast cancer: sequential treatment of high dose epirubicin, taxane, and cyclophosphamide concomitantly with a dual…
- Conditions
- Tubular Breast Cancer Stage II, Tubular Breast Cancer Stage III, Mucinous Breast Cancer Stage II, Breast Cancer Female NOS
- Trial name
- NCT02125344
- Testing
- non-pegylated liposomal doxorubicin, Carboplatin, Paclitaxel
- Where
- Germany
- Volunteers
- 961 people
- Sponsor
- GBG Forschungs GmbH
Early-stage Breast Cancer, Invasive Ductal Carcinoma of Female Breast
Radiation After No Axillary Nodal Sampling
This is a single arm, pilot, prospective study to evaluate the safety of partial breast irradiation in women who undergo breast conserving surgery without sentinel lymph node biopsy (SLNB) or axillary lymph node dissection…
- Trial name
- RADIANS (NCT07723209)
- Testing
- Partial Breast Irradiation (PBI)
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- NYU Langone Health
Breast Cancer Invasive
Pyrotinib, Trastuzumab, Pertuzumab and Nab-paclitaxel as Neoadjuvant Therapy in HER2-positive Breast Cancer
This study aims to evaluate the efficacy and safety of pyrotinib in combination with trastuzumab, pertuzumab and nab-paclitaxel as neoadjuvant therapy in early stage or locally advanced HER2-positive breast cancer.
- Trial name
- NCT04398914
- Testing
- Pyrotinib, Trastuzumab, Pertuzumab
- Where
- China
- Volunteers
- 216 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Breast Cancer
Radiofrequency Ablation in Treating Patients With Early Invasive Breast Cancer or Ductal Carcinoma in Situ
RATIONALE: Radiofrequency ablation uses a high-frequency, electric current to kill tumor cells. Giving radiofrequency ablation before surgery may make the tumor smaller and reduce the amount of normal tissue that needs to be…
- Trial name
- NCT00388115
- Testing
- conventional surgery, neoadjuvant therapy, radiofrequency ablation
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of California, Davis
Breast Cancer
Partial Breast Irradiation Using Non Invasive Approach for Early Stage Breast Cancer
The purpose of this study is to evaluate the rate of early and intermediate toxicity related to the AccuBoost System for delivery of APBI in women with resected, early stage breast cancer.
- Trial name
- NCT01463007
- Testing
- Accelerated partial breast irradiation, Extended Follow up
- Where
- 4 sites in United States
- Volunteers
- 40 people
- Sponsor
- Jaroslaw Hepel
Tubular Breast Cancer, Mucinous Breast Cancer
Addition of Cisplatin to Adjuvant Chemotherapy for Early Stage Breast Cancer in High-Risk Women
The investigators hypotheses that paclitaxel combined with cisplatin in a weekly-based regimen as adjuvant chemotherapy is more effective for high risk, HER2 negative breast cancer .
- Conditions
- Tubular Breast Cancer, Mucinous Breast Cancer, Invasive Duct Carcinoma of Breast
- Trial name
- NCT03201861
- Testing
- Paclitaxel, Cisplatin, EC to docetaxel or paclitaxel
- Where
- China
- Volunteers
- 762 people
- Sponsor
- RenJi Hospital
Invasive Breast Cancer Early Stages
Long-Term Follow-up Study of Early Stage Breast Cancer Patients Included in GEICAM Studies
This is a multicenter, cohorts study to collect information from patients diagnosed with early-stage invasive breast cancer who have been previously included in a neoadjuvant or adjuvant clinical trial of the GEICAM group.
- Trial name
- NCT03390894
- Where
- 73 sites in Spain
- Volunteers
- 8,000 people
- Sponsor
- Spanish Breast Cancer Research Group
Breast Cancer Stage I
Non Surgical Treatment (Microwave Ablation) of Breast Cancer
In the Netherlands approximately one out of seven women will develop breast cancer during her life. Most of these breast cancers are early stage, 40% of the women have stage 1.
- Trial name
- MASTER (NCT05887154)
- Testing
- Microwave ablation
- Volunteers
- 15 people
- Sponsor
- University Medical Center Groningen